Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | F7 | P08709 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17923292 | 1.00 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1POLBLMNAF7 | |
| SCHEMBL2766240 | 1.00 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1POLBLMNAF7 | |
| SCHEMBL2769652 | 0.86 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1POLBLMNAF7 | |
| SCHEMBL3881452 | 0.86 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1POLBLMNAF7 | |
| SCHEMBL12341890 | 0.86 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1POLBLMNAF7 | |
| SCHEMBL3893098 | 0.86 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1POLBLMNAF7 | |
| SCHEMBL28235670 | 0.85 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1POLBLMNAF7 | |
| SCHEMBL8321365 | 0.84 | ALDH1A1 (0.83) | ALDH1A1L3MBTL1POLBLMNAF7 | |
| SCHEMBL6227427 | 0.83 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1POLBLMNAF7 | |
| SCHEMBL28882020 | 0.82 | HSD17B10 (0.72) | ALDH1A1L3MBTL1POLBLMNAF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| EP-3699179-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| EP-2649076-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078915-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247815-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | MAPK1, MAPK11, MAPK14 | ALDH1A1 1717/4885L3MBTL1 3754/4885POLB 3697/4885 |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | ALDH1A1 2124/4885L3MBTL1 4652/4885POLB 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.